Tag: antibody

T-cell acute lymphoblastic leukemia or T-ALL is a biologically distinct form of leukemia. It's distinct from its B lymphoblastic or B-ALL counterpart and shows...

Antibody-drug conjugates (ADC) are effective antibody-based therapeutics for the treatment of cancer and hematological diseases. There is, however, an unmet medical need for the...

A new article, published by a team of writers including Muhammad Kalim, Jie Chen, and Shenghao Wang from the Department of Biochemistry and Genetics,...

Traditionally, the production of antibodies, considered the molecular workhorses of protein research, has been slow and complex. Less than a decade ago, generating research-grade...

Since the approval of the first antibody-drug conjugate or ADC, now more than 15 years ago, scientists and researchers have sent more than 50...

This week, during the World ADC Summit being held October 19 - 22, 2015 in San Diego, CA, Compugen presented the status of its predictive...

Earlier today, during a plenary session of the 2015 World ADC Summit, being held October 26-29, 2014 in San Diego, California, Randall Halcomb, PhD, Vice President Chemistry at Igenica Biotherapeutics, presented new data utilizing the company's SNAP site-specific ADC linker technology.

Earlier today, Sutro Biopharma, Inc, a biopharmaceutical company located in South San Francisco developing antibody drug conjugates and bispecific antibodies for targeted cancer therapies, and Merck Serono, the biopharmaceutical division of Merck KGaA (Darmstadt, Germany), the world’s oldest pharmaceutical and chemical company established in 1668 which operates as EMD Serono in the United States and Canada, announced that they will collaborate in developing Antibody-drug Conjugates or ADCs.

Antibody drug conjugates (ADCs) are a class of therapeutics that combine the selective targeting properties of monoclonal antibodies (mAbs) with potent cell killing activities of cytotoxic agents. Given rapid pace of progress in this field, it is important for drug developers to have a high level view of the landscape of ADCs in the clinic. This review analyzes ADCs tested in the field of Oncology. Trials are evaluated by cancer type, trial status, phase, and characteristics of the ADC.

Results from a preclinical trial shows that IMGN779, a novel, DNA-alkylating, anticancer therapeutics based on ImmunoGen, Inc, antibody-drug conjugates (ADC) technology, shows potent activity against CD33-expressing acute myeloid leukemia cells,including leukemic stem cells, while sparing normal cells.